BRIEF-Blueprint Medicines announces Proof-of-Concept Data from Global Phase 1 clinical trial of BLU-554 in patients with advanced Hepatocellular Carcinoma

* Blueprint Medicines announces proof-of-concept data from
global phase 1 clinical trial of BLU-554 in patients with
advanced Hepatocellular Carcinoma

The post BRIEF-Blueprint Medicines announces Proof-of-Concept Data from Global Phase 1 clinical trial of BLU-554 in patients with advanced Hepatocellular Carcinoma appeared first on NASDAQ.